World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
121
Citations
115561
World Ranking
3518
National Ranking
1935

Research.com Recognitions

  • 2018 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Jeffrey E. Gershenwald is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the field of Medicine, with a significant focus on Oncology, Molecular Biology, Immunology, Epidemiology, and Pulmonary and Respiratory Medicine.

The scientist's work covers several key topics, including:

  • Cutaneous Melanoma Detection and Management
  • CAR-T cell therapy research
  • Melanoma and MAPK Pathways
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Nonmelanoma Skin Cancer Studies
  • Brain Metastases and Treatment

Jeffrey E. Gershenwald has contributed to multiple recent publications. Selected papers include:

  • B cells and tertiary lymphoid structures promote immunotherapy response, 2020, Nature
  • Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response, 2021, Science
  • Cutaneous melanoma, 2023, The Lancet
  • Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade, 2021, Nature Medicine
  • Neoadjuvant relatlimab and nivolumab in resectable melanoma, 2022, Nature

The scientist collaborates frequently with several researchers, notably:

  • Jennifer A. Wargo
  • Michael A. Davies
  • Merrick I. Ross
  • Elizabeth M. Burton
  • Alexander J. Lazar

Prominent venues for their publications include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Annals of Surgical Oncology
  • Annals of Oncology
  • Nature

Among professional recognitions, Jeffrey E. Gershenwald was named a Fellow of the American Association for the Advancement of Science (AAAS) in 2018.

Best Publications

  • AJCC Cancer Staging Manual

    Mahul B. Amin;Stephen B. Edge;Frederick L. Greene;David R. Byrd

  • Final Version of 2009 AJCC Melanoma Staging and Classification

    Charles M. Balch;Jeffrey E. Gershenwald;Seng Jaw Soong;John F. Thompson

  • The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging

    Mahul B. Amin;Frederick L. Greene;Stephen B. Edge;Carolyn C. Compton;Carolyn C. Compton

  • Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

    V. Gopalakrishnan;V. Gopalakrishnan;C. N. Spencer;C. N. Spencer;L. Nezi;A. Reuben

  • The Immune Landscape of Cancer

    Vésteinn Thorsson;David L Gibbs;Scott D Brown;Denise Wolf

  • Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

    Charles M. Balch;Antonio C. Buzaid;Seng-Jaw Soong;Michael B. Atkins

  • Oncogenic Signaling Pathways in The Cancer Genome Atlas

    Francisco Sanchez-Vega;Marco Mina;Joshua Armenia;Walid K. Chatila

  • Genomic Classification of Cutaneous Melanoma

    Rehan Akbani;Kadir C. Akdemir;B. Arman Aksoy;Monique Albert

  • A landscape of driver mutations in melanoma

    Eran Hodis;Ian R. Watson;Ian R. Watson;Gregory V. Kryukov;Gregory V. Kryukov;Gregory V. Kryukov;Stefan T. Arold

  • Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

    Charles M. Balch;Seng-Jaw Soong;Jeffrey E. Gershenwald;John F. Thompson

  • Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

    Katherine A. Hoadley;Christina Yau;Christina Yau;Toshinori Hinoue;Denise M. Wolf

  • Comprehensive Characterization of Cancer Driver Genes and Mutations.

    Matthew H Bailey;Collin Tokheim;Eduard Porta-Pardo;Sohini Sengupta

  • B cells and tertiary lymphoid structures promote immunotherapy response

    Beth A. Helmink;Sangeetha M. Reddy;Jianjun Gao;Shaojun Zhang

  • Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

    Jeffrey E. Gershenwald;Richard A. Scolyer;Kenneth R. Hess;Vernon K. Sondak

  • Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

    Weiyi Peng;Jie Qing Chen;Chengwen Liu;Shruti Malu

  • Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients.

    Jeffrey E. Gershenwald;William Thompson;Paul F. Mansfield;Jeffrey E. Lee

  • Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

    Mark B. Faries;John F. Thompson;Alistair J. Cochran;Robert H. Andtbacka

  • Genomic and Functional Approaches to Understanding Cancer Aneuploidy

    Alison M. Taylor;Alison M. Taylor;Juliann Shih;Gavin Ha;Gavin Ha;Galen F. Gao

  • Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

    Pei Ling Chen;Whijae Roh;Alexandre Reuben;Zachary A. Cooper

  • Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma

    A. Gordon Robertson;Juliann Shih;Juliann Shih;Christina Yau;Ewan A. Gibb

Frequent Co-Authors

Merrick I. Ross
Merrick I. Ross The University of Texas MD Anderson Cancer Center
Jeffrey E. Lee
Jeffrey E. Lee The University of Texas MD Anderson Cancer Center
Michael A. Davies
Michael A. Davies The University of Texas MD Anderson Cancer Center
Janice N. Cormier
Janice N. Cormier The University of Texas MD Anderson Cancer Center
Victor G. Prieto
Victor G. Prieto The University of Texas MD Anderson Cancer Center
Alexander J. Lazar
Alexander J. Lazar The University of Texas MD Anderson Cancer Center
Paul F. Mansfield
Paul F. Mansfield The University of Texas MD Anderson Cancer Center
John F. Thompson
John F. Thompson University of Sydney
Jennifer A. Wargo
Jennifer A. Wargo The University of Texas MD Anderson Cancer Center
Richard A. Scolyer
Richard A. Scolyer Royal Prince Alfred Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in healthcare careers beyond medicine, many flexible online pathways are available. Online nursing degrees are among the most popular choices for those looking to quickly enter or advance within the field. For aspiring nurses with limited budgets, exploring the cheapest online bsn programs can provide a cost-effective way to earn a Bachelor of Science in Nursing without relocating.

Many practicing nurses or those wanting to specialize go for advanced degrees. The cheapest phd nursing programs help you pursue leadership roles in academics and research, while saving on educational costs.

If you hold a non-nursing bachelor’s degree but wish to switch careers, direct entry msn programs offer a fast-track route to becoming a registered nurse and earning a master’s in nursing.

For many, the easiest way to start a nursing career is through adn programs, which can be completed faster and with fewer prerequisites than BSN degrees.

Each of these paths provide stepping-stones to rewarding healthcare careers or further education in the medical field.

Best Scientists Citing Jeffrey E. Gershenwald

Trending Scientists